Cas:13721-43-2 tetrasodium,dioxido-oxo-phosphonato-λ5-phosphane manufacturer & supplier

Chemical Name:tetrasodium,dioxido-oxo-phosphonato-λ5-phosphane

CAS.NO:13721-43-2

Synonyms:tetrasodium dioxido-oxo-phosphonato;Tetrasodium hypophosphate;Hypophosphoric acid,sodium salt (1:4);tetrasodium hypodiphosphate;Hypophosphoric acid,tetrasodium salt

Molecular Formula:Na₄O₆P₂

Molecular Weight:249.90300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:146.00000

Exact Mass:249.87600

LogP:1.00960

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like tetrasodium dioxido-oxo-phosphonato chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Hypophosphoric acid,tetrasodium salt physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Hypophosphoric acid,tetrasodium salt Use and application,Tetrasodium hypophosphate technical grade,usp/ep/jp grade.

Related News: The mode of cooperation between domestic API companies and large international companies can lower the export threshold. tetrasodium,dioxido-oxo-phosphonato-λ5-phosphane manufacturer Raw material drug manufacturing is listed as one of the top ten key remediation industries, and it is necessary to implement clean transformation, new construction, reconstruction, and expansion of the ten key remediation industry construction projects to implement equal or reduced emissions of major pollutants; ) The industry implements the green enzyme production technology transformation; at the same time, the ten articles of water classify the industrial discharged sewage, and the sewage discharge of API companies is restricted. tetrasodium,dioxido-oxo-phosphonato-λ5-phosphane supplier The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. tetrasodium,dioxido-oxo-phosphonato-λ5-phosphane vendor An effective treatment for Alzheimer��s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally. tetrasodium,dioxido-oxo-phosphonato-λ5-phosphane factory The mode of cooperation between domestic API companies and large international companies can lower the export threshold.